{
    "q": [
        {
            "docid": "14499186_31",
            "document": "Eradication of infectious diseases . Onchocerciasis (river blindness) is the world's second leading cause of infectious blindness. It is caused by the nematode \"Onchocerca volvulus\", which is transmitted to people via the bite of a black fly. Elimination of this disease is under way in the region of the Americas, where this disease is endemic to Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela. The principal tool being used is mass ivermectin treatment. If successful, the only remaining endemic locations would be in Africa and Yemen. In Africa, it is estimated that greater than 102 million people in 19 countries are at high risk of onchocerciasis infection, and in 2008, 56.7 million people in 15 of these countries received community-directed treatment with ivermectin. Since adopting such treatment measures in 1997, the African Programme for Onchocerciasis Control reports a reduction in the prevalence of onchocerciasis in the countries under its mandate from a pre-intervention level of 46.5% in 1995 to 28.5% in 2008. Some African countries, such as Uganda, are also attempting elimination and successful elimination was reported in 2009 from two endemic foci in Mali and Senegal.",
            "score": 153.06738758087158
        },
        {
            "docid": "276846_23",
            "document": "Onchocerciasis . About 37 million people are infected with this parasite; about 300,000 of those had been permanently blinded. As of 2008, about 99% of onchocerciasis cases occurred in Africa. Onchocerciasis is currently endemic in 30 African countries, Yemen, and isolated regions of South America. Over 85 million people live in endemic areas, and half of these reside in Nigeria. Another 120 million people are at risk for contracting the disease. Due to the vector\u2019s breeding habitat, the disease is more severe along the major rivers in the northern and central areas of the continent, and severity declines in villages farther from rivers. Onchocerciasis was eliminated in the northern focus in Chiapas, Mexico, and the focus in Oaxaca, Mexico, where \"Onchocerca volvulus\" existed, was determined, after several years of treatment with ivermectin, as free of the transmission of the parasite.",
            "score": 132.40601015090942
        },
        {
            "docid": "14499186_23",
            "document": "Eradication of infectious diseases . Lymphatic filariasis is an infection of the lymph system by mosquito-borne microfilarial worms which can cause elephantiasis. Studies have demonstrated that transmission of the infection can be broken when a single dose of combined oral medicines is consistently maintained annually for approximately seven years. The strategy for eliminating transmission of lymphatic filariasis is mass distribution of medicines that kill the microfilariae and stop transmission of the parasite by mosquitoes in endemic communities. In sub-Saharan Africa, albendazole is being used with ivermectin to treat the disease, whereas elsewhere in the world albendazole is used with diethylcarbamazine. Using a combination of treatments better reduces the number of microfilariae in blood. Avoiding mosquito bites, such as by using insecticide-treated mosquito bed nets, also reduces the transmission of lymphatic filariasis. In the Americas, >90% of the burden of lymphatic filariasis is on the island of Hispaniola (comprising Haiti and the Dominican Republic). An elimination effort to address this is currently under way alongside the malaria effort described above; the Dominican Republic expects to eliminate its seven remaining foci by 2010, but lymphatic filariasis is still endemic to 110 of 140 communes in Haiti.",
            "score": 107.73093152046204
        },
        {
            "docid": "41081621_6",
            "document": "Taenia hydatigena . Cysticercosis is rare in the U.S. and most parts of Europe. It is primarily found in immigrant species, or species that have arrived from another country. The main objectives are as follows: to reduce the chances of becoming infected, and, if infected, to reduce the chances of the infection being transmitted. Educating the general public will help change how the disease is perceived. This could help people better understand risks and allow people to not live in fear of the disease. The high prevalence of some zoonotic helminths could indicate that humans in specific regions such as; the mediterranean area, south of the Sahara in the semi-arid areas of East Africa, South Africa, South America, East Europe and parts of China. These areas are at serious risk of transmission and, if all the preventive measures are not taken, the human infection may spread quickly. Preventive programs, such as elimination of the stray dogs from cities and rural regions, could be necessary in this instance. However, control of wild canids can be difficult, but there are other regulatory measures that can be applied to communities, such as health education and implementing strict regulations of livestock slaughtering in slaughter houses and farms, could reduce the risk of parasite transmission. In addition, it is important for public health authorities, pet owners, physicians and veterinarians in these regions to pay close attention to patients and to remain informed of any possible outbreaks and transmission. In a study conducted at Washington State University, the effects of heat treatment were analyzed on the young forms of Taenia hydatigena. They observed that when the eggs were treated at temperatures of 60 degrees C they did not establish in the hosts. This could be influential in future prevention methods.",
            "score": 86.53304147720337
        },
        {
            "docid": "22834821_10",
            "document": "Filarioidea . Various filarial diseases specific to humans are candidates for elimination by such means as breaking the cycle of infection. To eliminate the vectors is not really practical, but if the human population were sufficiently cleared of parasites by treatment with filaricides then one year without any human reservoirs of infection should suffice to exterminate the parasite. That is the intention of for example, the Global Programme to Eliminate Lymphatic Filariasis, which aims to interrupt transmission in that way.",
            "score": 73.54416394233704
        },
        {
            "docid": "1539801_27",
            "document": "Brugia malayi . A goal of community-based efforts is to eliminate microfilariae from the blood of infected individuals in order to prevent transmission to the mosquito. This is primarily accomplished through the use of drugs. The treatment for \"B. malayi\" infection is the same as for Bancroftian filariasis. Diethylcarbamazine has been used in mass treatment programs as an effective microfilaricidal drug in several locations, including India. While diethylcarbamazine tends to cause adverse reactions like immediate fever and weakness, it is not known to cause any long-term adverse drug effects. It has been shown to kill both adult worms and microfilariae. In Malaysia, diethylcarbamazine dosages (6\u00a0mg/kg weekly for 6 weeks; 6\u00a0mg/kg daily for 9 days) reduced microfilariae by 80% for 18\u201324 months after treatment in the absence of mosquito control. Microfilariae numbers slowly return many months after treatment, thus requiring multiple drug doses over time in order to achieve long-term control. However, it is not known how many years of mass drug administration is required to eliminate transmission. there have been any confirmed cases of diethylcarbamazine resistance as of 2007.",
            "score": 94.28279900550842
        },
        {
            "docid": "16964126_44",
            "document": "Oesophagostomum . This follow-up to the original two-year study by J.B. Ziem saw collaboration with the Lymphatic Filariasis Elimination Programme, essentially expanding the scope of the Oesophagostomum Intervention Research Program that Ziem worked under. 11 villages across northeastern Ghana were given albendazole-ivermectin treatment and monitored for changes in prevalence; once again, decreases in both \"Oesophagostomum\" and hookworm infections occurred after two years of mass treatment. However, after interrupting mass treatment, Oesophagostomum prevalence continued to decrease even as hookworm prevalence increased again. Human oesophagostomiasis infection thus seems interruptible; even small numbers of persistent Oesophagostomum post-treatment were not sufficient to cause reinfection.",
            "score": 84.46162962913513
        },
        {
            "docid": "3309982_10",
            "document": "Adenovirus infection . Safe and effective adenovirus vaccines were developed for adenovirus serotypes 4 and 7, but were available only for preventing ARD among US military recruits, and production stopped in 1996. Strict attention to good infection-control practices is effective for stopping transmission in hospitals of adenovirus-associated disease, such as epidemic keratoconjunctivitis. Maintaining adequate levels of chlorination is necessary for preventing swimming pool-associated outbreaks of adenovirus conjunctivitis. Most infections are mild and require no therapy or only symptomatic treatment. Because there is no virus-specific therapy, serious adenovirus illness can be managed only by treating symptoms and complications of the infection. Deaths are exceedingly rare but have been reported.",
            "score": 75.97172617912292
        },
        {
            "docid": "6028064_11",
            "document": "Lymphatic filariasis . The World Health Organization recommends mass deworming\u2014treating entire groups of people who are at risk with a single annual dose of two medicines, namely albendazole in combination with either ivermectin or diethylcarbamazine citrate. With consistent treatment, since the disease needs a human host, the reduction of microfilariae means the disease will not be transmitted, the adult worms will die out, and the cycle will be broken. In sub-Saharan Africa, albendazole (donated by GlaxoSmithKline) is being used with ivermectin (donated by Merck & Co.) to treat the disease, whereas elsewhere in the world, albendazole is used with diethylcarbamazine. Transmission of the infection can be broken when a single dose of these combined oral medicines is consistently maintained annually for a duration of four to six years. Using a combination of treatments better reduces the number of microfilariae in blood. Avoiding mosquito bites, such as by using insecticide-treated mosquito bed nets, also reduces the transmission of lymphatic filariasis.",
            "score": 88.08319902420044
        },
        {
            "docid": "203312_37",
            "document": "Management of HIV/AIDS . In the first 6 months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease. There may be special benefits to starting antiretroviral therapy early during this acute phase, including lowering the viral \"set-point\" or baseline viral load, reduce the mutation rate of the virus, and reduce the size of the viral reservoir (See section below on viral reservoirs). The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped. Since viral loads are usually very high during acute infection, this period carries an estimated 26 times higher risk of transmission. By treating acutely infected patients, it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are associated with lower risk of transmission (See section on treatment as prevention). However an overall benefit has not been proven and has to be balanced with the risks of HIV treatment. Therapy during acute infection carries a grade BII recommendation from the US DHHS.",
            "score": 88.19912016391754
        },
        {
            "docid": "23339740_10",
            "document": "Mass drug administration . Two trials in Northern Nigeria combined multiple rounds of MDA and insecticide spraying. The first trial, in Kankiya, included 11 rounds of MDA combined with 8 rounds of DDT indoor spraying. The study was based on computer-aided models that showed that MDA could eradicate malaria in the study area if combined with an appropriate \u2018insecticide attack\u2019. Following MDAs, parasite prevalence dropped from 19% to\u00a01%. The investigators did not consider this a success because parasite prevalence increased again after the interventions were stopped. Entomological indices also showed only a temporary reduction in transmission, which was completely reversed after the control measures ceased. Because the investigators felt that the failure of the trial to interrupt transmission was due to operational inadequacies, they recommended a much larger and more sophisticated evaluation of insecticide spraying combined with MDA. This recommendation helped to launch the Garki project, also in Northern Nigeria, in 1969. In the Garki project, all 164 study villages in the catchment area were sprayed with propoxur, a residual insecticide. In addition, in 60 villages, MDA with sulfalene / pyrimethamine was given at 10-week intervals for two years. In two small village clusters, house spraying was supplemented with larvicide and MDA every two weeks. With biweekly MDA, parasite prevalence fell to\u00a01% in the dry season and to\u00a05% in the rainy season. MDA given every 10 weeks resulted in a parasite prevalence of 2% in the dry season and 28% in the rainy season. Transmission was not interrupted with either MDA regime. The authors concluded that spraying of residual insecticides and MDA did not result in a sustainable interruption of malaria transmission.",
            "score": 55.42347955703735
        },
        {
            "docid": "1877407_10",
            "document": "Onchocerca volvulus . \"Onchocerca volvulus\" causes onchocerciasis, which causes severe itching. Long-term infection can cause keratitis, an inflammation of the cornea in the eye, and ultimately leads to blindness. Symptoms are caused by the microfilariae and the immune response to infection, rather than the adults themselves. The most effective treatment involves using ivermectin, although there are reports of resistance developing to this drug. Ivermectin prevents female worms from releasing microfilariae for several months, thus relieving symptoms and temporarily preventing transmission. However, this does not kill adult worms so it must be taken once annually as long as adult worms are present.",
            "score": 88.93773341178894
        },
        {
            "docid": "276846_18",
            "document": "Onchocerciasis . In mass drug administration (MDA) programmes, the treatment for onchocerciasis is ivermectin (trade name: Mectizan); infected people can be treated with two doses of ivermectin, six months apart, repeated every three years. The drug paralyses and kills the microfilariae causing fever, itching, and possibly oedema, arthritis and lymphadenopathy. Intense skin itching is eventually relieved, and the progression towards blindness is halted. In addition, while the drug does not kill the adult worms, it does prevent them for a limited time from producing additional offspring. The drug therefore prevents both morbidity and transmission for up to several months.",
            "score": 103.23958945274353
        },
        {
            "docid": "23339740_3",
            "document": "Mass drug administration . This article describes the administration of antimalarial drugs to whole populations an intervention which has been used as a malaria-control measure for more than 70 years. Recent proposals to eliminate or even to eradicate malaria have led to a renewed interest in mass drug administrations in areas with very high malaria endemicity. Drugs have been administered either directly as a full therapeutic course of treatment or indirectly through the fortification of salt. Mass drug administrations were generally unsuccessful in interrupting transmission but, in some cases, had a marked effect on parasite prevalence and on the incidence of clinical malaria. MDAs are likely to encourage the spread of drug-resistant parasites and so have only a limited role in malaria control. They may have a part to play in the management of epidemics and in the control of malaria in areas with a very short transmission season. In order to reduce the risk of spreading drug resistance, MDAs should use more than one drug and, preferably include a drug, such as an artemisinin, which has an effect on gametocytes. MDAs have low acceptance in areas with low malaria endemicity.",
            "score": 69.05931460857391
        },
        {
            "docid": "41375108_17",
            "document": "Julio Montaner . Based on data from Taiwan and British Columbia, Montaner and his colleagues posited that approximately a 50% reduction in HIV transmission could be attributed to widespread HAART adherence. This suggested that Treatment as Prevention was a cost-effective strategy, based on an estimated lifetime treatment cost of $241 000 in 2001 in the United States for a new HIV infection. Montaner and his colleagues created a hypothetical population-based model that demonstrated that with worldwide access to HAART, the short-term cost would be much less compared to the long-term cost of treating new infections as a result of the decrease in transmission rate. Their population-based model demonstrated, in an optimistic prediction, that HIV global prevalence could be reduced by a factor of 70 over 45 years. Montaner\u2019s research also addressed concerns of HIV drug resistance evolving from increased and early access to HAART by citing evidence from studies supporting the idea that fears of drug resistance should not prevent widespread HAART distribution. In a 2011 article published in Lancet, Montaner stated that \u201cThe evidence is in: treatment is prevention. Treatment dramatically prevents morbidity and mortality, HIV transmission, and tuberculosis. Furthermore, treatment prevents HIV transmission in vertical, sexual, and injection drug use settings; indeed, a very welcome double hat-trick. The challenge remains to optimise the impact of this valuable intervention. Failure to do so is not an option.\u201d Montaner cited the findings of the landmark study HPTN 052, that HAART use can reduce HIV transmission by 96% in sero-discordant heterosexual couples, as compelling evidence for implementing the \u201cTreatment as Prevention\u201d Strategy. These findings supported the BC-CfE\u2019s finding of a negative correlation between an increased number of HIV positive individuals on HAART and new cases of HIV. These results were from a population-based study in B.C. that aimed to estimate the correlation between new HIV infections, HAART coverage and HIV-1 plasma viral load published in Lancet in 2010.",
            "score": 83.23136389255524
        },
        {
            "docid": "276846_2",
            "document": "Onchocerciasis . Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm \"Onchocerca volvulus\". Symptoms include severe itching, bumps under the skin, and blindness. It is the second-most common cause of blindness due to infection, after trachoma. The parasite worm is spread by the bites of a black fly of the \"Simulium\" type. Usually, many bites are required before infection occurs. These flies live near rivers, hence the common name of the disease. Once inside a person, the worms create larvae that make their way out to the skin, where they can infect the next black fly that bites the person. There are a number of ways to make the diagnosis, including: placing a biopsy of the skin in normal saline and watching for the larva to come out, looking in the eye for larvae, and looking within the bumps under the skin for adult worms. A vaccine against the disease does not exist. Prevention is by avoiding being bitten by flies. This may include the use of insect repellent and proper clothing. Other efforts include those to decrease the fly population by spraying insecticides. Efforts to eradicate the disease by treating entire groups of people twice a year are ongoing in a number of areas of the world. Treatment of those infected is with the medication ivermectin every six to twelve months. This treatment kills the larvae but not the adult worms. The antibiotic doxycycline weakens the worms by killing an associated bacterium called \"Wolbachia\", and is recommended by some as well. The lumps under the skin may also be removed by surgery. About 15.5 million people are infected with river blindness. Approximately 0.8 million have some amount of loss of vision from the infection. Most infections occur in sub-Saharan Africa, although cases have also been reported in Yemen and isolated areas of Central and South America. In 1915, the physician Rodolfo Robles first linked the worm to eye disease. It is listed by the World Health Organization (WHO) as a neglected tropical disease.",
            "score": 91.34643614292145
        },
        {
            "docid": "186641_33",
            "document": "Loa loa filariasis . In Central and West Africa, initiatives to control onchocerciasis involve mass treatment with Ivermectin. However, these regions typically have high rates of co-infection with both \"L. loa\" and \"O. volvulus\", and mass treatment with Ivermectin can have severe adverse effects (SAE). These include hemorrhage of the conjunctiva and retina, heamaturia, and other encephalopathies that are all attributed to the initial L. loa microfilarial load in the patient prior to treatment. Studies have sought to delineate the sequence of events following Ivermectin treatment that lead to neurologic SAE and sometimes death, while also trying to understand the mechanisms of adverse reactions to develop more appropriate treatments.",
            "score": 106.63014209270477
        },
        {
            "docid": "25015196_3",
            "document": "United Front Against Riverblindness . UFAR and its partners use the community-directed treatment with ivermectin (CDTI) approach recommended by the African Programme for Onchocerciasis Control (APOC), a branch of the World Health Organization (WHO). Each year UFAR ensures the treatment of about one million people in what is referred to as the CDTI Kasongo project to prevent the further transmission of the parasitic disease onchocerciasis to uninfected persons and to halt the progression of the disease in those already infected.",
            "score": 113.00483632087708
        },
        {
            "docid": "34177408_4",
            "document": "HPTN 052 . After the finding of such a drastic reduction in transmission the control arm was stopped prematurely in 2011 and all participants were offered ART. Couples were followed for four more years and by 2015, 1,171 couples were still being followed when the study was completed. As reported in a follow-up publication in the New England Journal of Medicine, only 8 cases of HIV transmission were recorded from patients on ART and 4 of them happened in the first three months after treatment was started and before the virus was able to be suppressed. The other 4 were in patients who had detectable levels of virus in their blood despite being on ART, likely due to resistance and virologic failure. Overall there was a sustained 93% reduction in HIV transmission.",
            "score": 70.89847660064697
        },
        {
            "docid": "23339740_23",
            "document": "Mass drug administration . Whether MDAs can be considered successful or not depends on the expectation of what they might achieve; many studies do not define whether their main aim was to interrupt transmission or to control disease. When MDAs were used as part of an attempt to interrupt transmission completely, they almost always failed. Only one project, conducted on Aneityum, a small isolated island in the Pacific, succeeded in permanently interrupting transmission using MDA as one of several malaria-control strategies. However, although unable to interrupt transmission, many MDA projects led to a marked reduction in parasite prevalence and probably had a marked also transient effect on malaria-related morbidity and mortality. Most of the early trials used study designs which would now be considered inadequate to provide a definitive answer on study outcome. For example, before-and-after comparisons were used frequently. Such comparisons are especially unreliable for vector-borne diseases which may show marked variations in incidence from season to season as well as from year to year. Furthermore, in several studies only a single intervention and control area or group were compared despite the fact a single control group cannot provide statistically interpretable results (see \"n\"\u00a0=\u00a01 fallacy).",
            "score": 55.21384155750275
        },
        {
            "docid": "23339740_7",
            "document": "Mass drug administration . The first, well documented use of direct MDA took place in a rubber plantation in Liberia in 1931. Two doses of the 8-aminoquinoline plasmoquine were given weekly to workers and their families in two camps. The prevalences of malaria parasite infections in humans and anopheline mosquitoes before and after treatment were studied. The authors concluded that \u2018the fall in the mosquito infection rate of the two plasmoquine treated camps was so large as to indicate a local disappearance, or at least a great reduction, in gametocyte carriers in the treated population\u2019. No long-term follow up data were provided for this study or most of the trials reported subsequently. The next documented use of MDA in sub-Saharan Africa took place in 1948 and 1949 in tea estates in Kericho, Kenya. Ten thousand inhabitants of the tea estates received twice weekly proguanil from April to July 1948. The intervention was supplemented with DDT spraying in March and June of the following year. Before the intervention the mean malaria incidence in July, the peak of the malaria transmission season, was 56 cases per 1000 population. Following the intervention 4 malaria cases were detected in July 1949. The author therefore recommended continuation of twice weekly proguanil prophylaxis on the estates. The Nandi district of Kenya was the scene of a large MDA in 1953 and 1954. The target population of 83,000 received a single dose of pyrimethamine at the beginning of the malaria season in 1953 and 1954. The coverage was estimated to be around 95%. Before the intervention severe malaria epidemics had been reported in the area. Following the intervention the parasite prevalence dropped from 23% to 2.3%. The author states that in a control area parasite prevalence rose over the same period to over 50%. It was felt that the MDA was effective in curbing severe malaria epidemics. In the following three years, 1955 to 1957, pyrimethamine administration was replaced with Dieldrin spraying to consolidate malaria control, which makes an assessment of the long-term effect of this MDA impossible.",
            "score": 64.79010343551636
        },
        {
            "docid": "186641_44",
            "document": "Loa loa filariasis . One drug that has been proposed for the treatment of onchocerciasis is doxycycline. This drug has been shown to be effective in killing both the adult worm of \"O. volvulus\" and \"Wolbachia\", the bacteria believed to play a major role in the onset of onchocerciasis, while having no effect on the microfilariae of \"L. loa\". In a study done at 5 different co-endemic regions for onchocerciasis and loiasis, doxycycline was shown to be effective in treating over 12,000 individuals infected with both parasites with minimal complications. Drawbacks to using Doxycycline include bacterial resistance and patient compliance because of a longer treatment regimen and emergence of doxycycline-resistant \"Wolbachia\". However, in the study over 97% of the patients complied with treatment, so it does pose as a promising treatment for onchocerciasis, while avoiding complications associated with L. loa co-infections.",
            "score": 104.46666407585144
        },
        {
            "docid": "34177408_3",
            "document": "HPTN 052 . As reported by a 2011 publication in the \"New England Journal of Medicine\", in the trial there were 1763 couples, where only one partner was infected with HIV. After following them for a median of 1.7 years, there were 4 HIV infections in the group on ART and 35 in the group not on ART. However, when comparing the HIV viruses in the 4 infections in the ART group, 3 of them were different than that of the partner who had originally had HIV. It is likely that these were contracted from another sexual partner, who was not involved in the trial. Therefore, only 1 transmission was recorded in the ART group with 886 couples followed for almost 2 years. That was estimated to be a 96% reduction from the control group, who had only started on ART if they had become sick or their CD4 cell counts had dropped below 250. It is also notable that both groups had received extensive counseling, condoms, and STI treatment.",
            "score": 62.871509075164795
        },
        {
            "docid": "2221355_11",
            "document": "Staphylococcus hominis . In 2002 and 2003, 32 isolates of SHN were found in 21 patients. Twenty-three of these were from blood cultures, six from catheters, one from cerebrospinal fluid, one from a wound, and one from external ear fluid. Eighteen of the 21 patients from whom these isolates were recovered were neonates, one was a 13-year-old boy, and two were adults. Thirteen of these cases were confirmed as sepsis in neonates resulting from SHN infection. These were the first clinical reports of SHN causing bacterimia in hospitalized patients. SHN infections were high in morbidity, but had a low rate of mortality. More undocumented instances of SHN infections may not have been reported because not all coagulase-negative staphlococcal infections (CONs) are identified to the species level. Molecular epidemiology was successful in tracing 13 cases of sepsis in neonates to a single clone of SHN during a two-year study period in neonatal ICUs. Formal investigation regarding the mode of transmission this microbe uses were not conducted, but infants are believed to serve as reservoirs for the microorganism, and transmission takes place with contact between health workers and the infants. In addition, staphylococcal isolates from the nasopharynges and hands of health care workers were shown to be genetically similar to those that colonize or cause disease in neonates. This supports the idea that health workers serve as a form of nosocomical transmission of CONs. If SHN indeed takes residence on human skin, it probably exists in small numbers and would require enrichment for detection.  SHN has also been responsible for nosocomial outbreaks elsewhere. SHN strains have been causing bloodstream infections, but have still been classified as vancomycin-susceptible.",
            "score": 56.45448815822601
        },
        {
            "docid": "368736_6",
            "document": "Misconceptions about HIV/AIDS . High levels of HIV-1 (often HAART-resistant) develop if treatment is stopped, if compliance with treatment is inconsistent, or if the virus spontaneously develops resistance to an individual's regimen. Antiretroviral treatment known as post-exposure prophylaxis reduces the chance of acquiring an HIV infection when administered within 72 hours of exposure to HIV. These problems mean that while HIV-positive people with low viremia are less likely to infect others, the chance of transmission always exists. In addition, people on HAART may still become sick.",
            "score": 71.49756574630737
        },
        {
            "docid": "23562433_16",
            "document": "Texas phoenix palm decline . To favor development, the area of infection must have a high population of insect vectors (planthoppers, psyllids, or treehoppers) for continuous, successful transmission. Rate of replication depends on the parameter of the incubation period. Depending on the insect vector and temperature, it could be anywhere between 10 (at 30\u00b0) and 45 (at 10\u00b0) days. The concentration of phytoplasmas, at the salivary glands of the insect vector after incubation period, also varies transmission. The concentration must meet a certain level before the insect transfers the infection into new plants.",
            "score": 46.141682386398315
        },
        {
            "docid": "22535120_7",
            "document": "Aeromonas salmonicida . Transmission of furunculosis mainly occurs through fish-to-fish contact by the skin or by ingestion. Rainbow trout have been found to carry \"A. salmonicida\" up to two years after initial infection without re-exposure. Chemically immunosuppressed fish compared with temperature-stressed fish had a 73% mortality as opposed to a 33% mortality rate, respectively. Naturally occurring trout infections consisted of a 5\u20136% mortality rate per week with an 85% rate in untreated populations. Some clinical furunculosis survivors of an infected trout population became \"A. salmonicida\" carriers. When comparing furunculosis epidemics with depressed oxygen levels, when oxygen concentrations were decreased to less than 5\u00a0mg/l, \"A. salmonicida\" concentrations increased. While observing chum salmon in a density of 14.7 fish per square meter, 12.4% were infected with \"A. salmonicida\", whereas, densities at 4.9 fish per square meter were infection-free. Additionally, \"A. salmonicida\" concentrations were considerably elevated in water with low dissolved oxygen (6\u20137\u00a0mg/l), compared to water with higher dissolved oxygen (10\u00a0mg/l). High density-low oxygen water resulted in survival rates that were roughly 40% less than in those consisting of low density-high oxygen conditions.",
            "score": 44.927979588508606
        },
        {
            "docid": "15925628_36",
            "document": "Hepatitis B . The primary method of transmission reflects the prevalence of chronic HBV infection in a given area. In low prevalence areas such as the continental United States and Western Europe, injection drug abuse and unprotected sex are the primary methods, although other factors may also be important. In moderate prevalence areas, which include Eastern Europe, Russia, and Japan, where 2\u20137% of the population is chronically infected, the disease is predominantly spread among children. In high-prevalence areas such as China and South East Asia, transmission during childbirth is most common, although in other areas of high endemicity such as Africa, transmission during childhood is a significant factor. The prevalence of chronic HBV infection in areas of high endemicity is at least 8% with 10\u201315% prevalence in Africa/Far East. As of 2010, China has 120\u00a0million infected people, followed by India and Indonesia with 40\u00a0million and 12\u00a0million, respectively. According to World Health Organization (WHO), an estimated 600,000 people die every year related to the infection.",
            "score": 62.19052755832672
        },
        {
            "docid": "203312_23",
            "document": "Management of HIV/AIDS . A separate argument for starting antiretroviral therapy that has gained more prominence is its effect on HIV transmission. ART reduces the amount of virus in the blood and genital secretions. This has been shown to lead to dramatically reduced transmission of HIV when one partner with a suppressed viral load (<50 copies/ml) has sex with a partner who is HIV negative. In clinical trial HPTN 052, 1763 serodiscordant heterosexual couples in 9 countries were planned to be followed for at least 10 years, with both groups receiving education on preventing HIV transmission and condoms, but only one group getting ART. The study was stopped early (after 1.7 years) for ethical reasons when it became clear that antiviral treatment provided significant protection. Of the 28 couples where cross-infection had occurred, all but one had taken place in the control group consistent with a 96% reduction in risk of transmission while on ART. The single transmission in the experimental group occurred early after starting ART before viral load was likely to be suppressed. The term \"Pre-Exposure Prophylaxis (PrEP)\" refers to the concept of providing HIV- individuals with medication\u2014in conjunction with safer-sex education and regular HIV/STI screenings\u2014in order to reduce the risk of acquiring HIV. In 2011, the journal \"Science\" gave the Breakthrough of the Year award to treatment as prevention.",
            "score": 82.89172506332397
        },
        {
            "docid": "19222449_5",
            "document": "HIV/AIDS in Peru . Infections with syphilis, gonorrhea, and Chlamydia in men and women and trichomoniasis and bacterial vaginosis in women are factors in the increasing risk of HIV transmission in Peru. According to the 2009 Demographic and Health Survey, 14 percent of the women surveyed among those reporting history of sexual intercourse reported having sexually transmitted infection (STI) symptoms. Inadequate and ineffective treatment of STIs is common in Peru. Inadequate and ineffective treatment of sexually transmitted infections (STIs) is common. Also of significant concern is the high HIV prevalence among prison inmates. Given the relatively low level of sexual education, limited condom use, and risky sexual behaviors practiced by some subpopulations, including multiple sex partners, there is a significant potential for the further spread of HIV in Peru. According to the 2008 UNGASS report, less than 5 percent of schools offer sex education, including information about HIV (USAID 2010). One study by Klausner and Mendoza (2002) of young people aged 18 to 30 in 34 neighborhoods in Lima, Chiclayo, and Trujillo demonstrated that 18 percent had more than one sex partner in the last year, 8 percent had more than one partner in the last three months, and condom use was low.",
            "score": 65.81940543651581
        },
        {
            "docid": "19227237_12",
            "document": "HIV/AIDS in Haiti . Prior to the efforts to eliminate vertical transmission of HIV, around 27% of babies born to HIV infected mothers in Haiti contracted the virus from their mothers through breast milk. As a preventative measure, GHESKIO and the Ministry of Health set up national guidelines for HIV infected mothers and newborn babies to receive doses of zidovudine. Since 2003, Haiti has altered its guidelines to allow triple drug ART for pregnant HIV infected women, treatments for existing opportunistic infections, and counseling on the use of formula feed instead of breast milk to lower transmission rates. Since the use of triple therapy, HIV transmission rates from mother to child for those on triple drug ART has decreased to around 1.9%, while the transmission rates among all pregnant women treated for HIV in any form has dropped to 9.2%, both of which are significant decreases from the initial 27% vertical transmission. The Joint Team and UNICEF also provides manuals on preventing mother to child transmission of HIV and offers prenatal and postpartum counseling services to HIV infected mothers to stem vertical transmission in Haiti. However, further educational efforts are necessary as only around 40% of Haitian HIV infected mothers attend these counseling services, and an even smaller amount get tested for HIV prior to childbirth. Around 80% of Haitians recognize that the virus can be transmitted vertically, however, the majority of Haitians do not know that treatment of both the mother and child in the weeks before and after childbirth can greatly decrease the risk of infection in the baby. This coupled with the fact that around 80% of childbirth in Haiti takes place at home instead of in a hospital necessitates that further connection of HIV infected individuals with the health networks in Haiti is essential to stem vertical transmission.",
            "score": 78.12073016166687
        },
        {
            "docid": "20423_32",
            "document": "Malaria . Vector control refers to methods used to decrease malaria by reducing the levels of transmission by mosquitoes. For individual protection, the most effective insect repellents are based on DEET or picaridin. Insecticide-treated mosquito nets (ITNs) and indoor residual spraying (IRS) have been shown to be highly effective in preventing malaria among children in areas where malaria is common. Prompt treatment of confirmed cases with artemisinin-based combination therapies (ACTs) may also reduce transmission.",
            "score": 60.132956981658936
        }
    ],
    "r": [
        {
            "docid": "14499186_31",
            "document": "Eradication of infectious diseases . Onchocerciasis (river blindness) is the world's second leading cause of infectious blindness. It is caused by the nematode \"Onchocerca volvulus\", which is transmitted to people via the bite of a black fly. Elimination of this disease is under way in the region of the Americas, where this disease is endemic to Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela. The principal tool being used is mass ivermectin treatment. If successful, the only remaining endemic locations would be in Africa and Yemen. In Africa, it is estimated that greater than 102 million people in 19 countries are at high risk of onchocerciasis infection, and in 2008, 56.7 million people in 15 of these countries received community-directed treatment with ivermectin. Since adopting such treatment measures in 1997, the African Programme for Onchocerciasis Control reports a reduction in the prevalence of onchocerciasis in the countries under its mandate from a pre-intervention level of 46.5% in 1995 to 28.5% in 2008. Some African countries, such as Uganda, are also attempting elimination and successful elimination was reported in 2009 from two endemic foci in Mali and Senegal.",
            "score": 153.0673828125
        },
        {
            "docid": "276846_23",
            "document": "Onchocerciasis . About 37 million people are infected with this parasite; about 300,000 of those had been permanently blinded. As of 2008, about 99% of onchocerciasis cases occurred in Africa. Onchocerciasis is currently endemic in 30 African countries, Yemen, and isolated regions of South America. Over 85 million people live in endemic areas, and half of these reside in Nigeria. Another 120 million people are at risk for contracting the disease. Due to the vector\u2019s breeding habitat, the disease is more severe along the major rivers in the northern and central areas of the continent, and severity declines in villages farther from rivers. Onchocerciasis was eliminated in the northern focus in Chiapas, Mexico, and the focus in Oaxaca, Mexico, where \"Onchocerca volvulus\" existed, was determined, after several years of treatment with ivermectin, as free of the transmission of the parasite.",
            "score": 132.406005859375
        },
        {
            "docid": "25015196_3",
            "document": "United Front Against Riverblindness . UFAR and its partners use the community-directed treatment with ivermectin (CDTI) approach recommended by the African Programme for Onchocerciasis Control (APOC), a branch of the World Health Organization (WHO). Each year UFAR ensures the treatment of about one million people in what is referred to as the CDTI Kasongo project to prevent the further transmission of the parasitic disease onchocerciasis to uninfected persons and to halt the progression of the disease in those already infected.",
            "score": 113.00483703613281
        },
        {
            "docid": "14499186_23",
            "document": "Eradication of infectious diseases . Lymphatic filariasis is an infection of the lymph system by mosquito-borne microfilarial worms which can cause elephantiasis. Studies have demonstrated that transmission of the infection can be broken when a single dose of combined oral medicines is consistently maintained annually for approximately seven years. The strategy for eliminating transmission of lymphatic filariasis is mass distribution of medicines that kill the microfilariae and stop transmission of the parasite by mosquitoes in endemic communities. In sub-Saharan Africa, albendazole is being used with ivermectin to treat the disease, whereas elsewhere in the world albendazole is used with diethylcarbamazine. Using a combination of treatments better reduces the number of microfilariae in blood. Avoiding mosquito bites, such as by using insecticide-treated mosquito bed nets, also reduces the transmission of lymphatic filariasis. In the Americas, >90% of the burden of lymphatic filariasis is on the island of Hispaniola (comprising Haiti and the Dominican Republic). An elimination effort to address this is currently under way alongside the malaria effort described above; the Dominican Republic expects to eliminate its seven remaining foci by 2010, but lymphatic filariasis is still endemic to 110 of 140 communes in Haiti.",
            "score": 107.73092651367188
        },
        {
            "docid": "186641_33",
            "document": "Loa loa filariasis . In Central and West Africa, initiatives to control onchocerciasis involve mass treatment with Ivermectin. However, these regions typically have high rates of co-infection with both \"L. loa\" and \"O. volvulus\", and mass treatment with Ivermectin can have severe adverse effects (SAE). These include hemorrhage of the conjunctiva and retina, heamaturia, and other encephalopathies that are all attributed to the initial L. loa microfilarial load in the patient prior to treatment. Studies have sought to delineate the sequence of events following Ivermectin treatment that lead to neurologic SAE and sometimes death, while also trying to understand the mechanisms of adverse reactions to develop more appropriate treatments.",
            "score": 106.63014221191406
        },
        {
            "docid": "186641_44",
            "document": "Loa loa filariasis . One drug that has been proposed for the treatment of onchocerciasis is doxycycline. This drug has been shown to be effective in killing both the adult worm of \"O. volvulus\" and \"Wolbachia\", the bacteria believed to play a major role in the onset of onchocerciasis, while having no effect on the microfilariae of \"L. loa\". In a study done at 5 different co-endemic regions for onchocerciasis and loiasis, doxycycline was shown to be effective in treating over 12,000 individuals infected with both parasites with minimal complications. Drawbacks to using Doxycycline include bacterial resistance and patient compliance because of a longer treatment regimen and emergence of doxycycline-resistant \"Wolbachia\". However, in the study over 97% of the patients complied with treatment, so it does pose as a promising treatment for onchocerciasis, while avoiding complications associated with L. loa co-infections.",
            "score": 104.46666717529297
        },
        {
            "docid": "47237702_4",
            "document": "Uche Veronica Amazigo . In her early career, Amazigo was a senior lecturer at the University of Nigeria in Nsukka, where she taught medical parasitology and public health. It was during this period in the late 1970s that she began studying onchocerciasis (river blindness) after encountering the disease during her travels around the area. She joined a rural women's support group in order to better study the social effects that the disease had on rural communities. She then applied for and received a research grant from the United Nations\u2019 Special Programme for Research and Training in Tropical Diseases (TDR) in order to continue her research into river blindness. She then worked for the TDR for several years, where she developed a program for training community workers to treat themselves and others, and keep record books of the treatments. She brought her findings to the WHO, where her studies were replicated. The results from this replication resulted in the founding of the African Programme for Onchocerciasis Control (APOC) in 1995. Amazigo joined the APOC as a scientist in 1996. Her work with the APOC built upon her work with the TDR, and resulted in the development of Community-Directed Treatment with Ivermectin (CDTI), with ivermectin being the drug that treats onchocerciasis. It is estimated that her CDTI strategy has resulted in the treatment of over 112.4 million people for onchocerciasis, 11 million people for malaria control, and 37 million people for the control of other diseases. Amazigo spent four years as the Chief of the WHO's sustainable drug distribution unit from 2001-2005. She served as the director of the APOC from 2005 until 2011. During this period, she engaged 16 African governments, 14 international non-governmental organizations (NGOs), 20 bilateral and multi-lateral donors, and pharmaceutical companies. After retiring from the APOC, she founded the Pan-African Community Initiative on Education and Health (PACIEH) in 2013.",
            "score": 104.21270751953125
        },
        {
            "docid": "1117429_4",
            "document": "Ivermectin . Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas, and to stop transmission of lymphatic filariasis and onchocerciasis around the world in programs sponsored by the Carter Center using ivermectin donated by Merck. The disease is common in 30 African countries, six Latin American countries, and Yemen. The drug rapidly kills microfilariae, but not the adult worms. A single oral dose of ivermectin, taken annually for the 1015-year lifespan of the adult worms, is all that is needed to protect the individual from onchocerciasis.",
            "score": 103.54718780517578
        },
        {
            "docid": "276846_15",
            "document": "Onchocerciasis . In 1995, the African Programme for Onchocerciasis Control began covering another 19 countries, mainly relying upon the use of ivermectin. Its goal is to set up a community-directed supply of ivermectin for those who are infected. In these ways, transmission has declined. In 2015, WHO was facilitating launch of an elimination program in Yemen.",
            "score": 103.27393341064453
        },
        {
            "docid": "276846_18",
            "document": "Onchocerciasis . In mass drug administration (MDA) programmes, the treatment for onchocerciasis is ivermectin (trade name: Mectizan); infected people can be treated with two doses of ivermectin, six months apart, repeated every three years. The drug paralyses and kills the microfilariae causing fever, itching, and possibly oedema, arthritis and lymphadenopathy. Intense skin itching is eventually relieved, and the progression towards blindness is halted. In addition, while the drug does not kill the adult worms, it does prevent them for a limited time from producing additional offspring. The drug therefore prevents both morbidity and transmission for up to several months.",
            "score": 103.23958587646484
        },
        {
            "docid": "12271250_26",
            "document": "Mansonella perstans . While ivermectin is considered a first-line agent for the treatment of many filarial diseases (especially onchocerciasis), it has shown little or no efficacy against \"M. perstans\" at a dose of 200\u00a0\u03bcg/kg body weight or at a dose of 600\u00a0\u03bcg/kg body weight. A 2009 study in Uganda evaluated the effects of ivermectin, albendazole, and a combined regimen of both drugs on \"M. perstans\" infected individuals: Single doses of ivermectin alone had no marked effect on \"M. perstans\" microfilaraemias in the 12 months after treatments, with the counts remaining to pretreatment values. This is consistent with the findings of previous studies which have suggested ivermectin, when used alone, has little or no effect on \"M. perstans\" microfilaraemias. A reduction of microfilariae in patients has been noted, but it takes a long time to achieve (over 3 yr of administration of ivermectin), and is thus not useful in the short term for symptomatic patients.",
            "score": 98.91963958740234
        },
        {
            "docid": "276846_14",
            "document": "Onchocerciasis . Various control programs aim to stop onchocerciasis from being a public health problem. The first was the Onchocerciasis Control Programme (OCP), which was launched in 1974, and at its peak, covered 30 million people in 11 countries. Through the use of larvicide spraying of fast-flowing rivers to control black fly populations, and from 1988 onwards, the use of ivermectin to treat infected people, the OCP eliminated onchocerciasis as a public health problem. The OCP, a joint effort of the World Health Organisation, the World Bank, the United Nations Development Programme, and the UN Food and Agriculture Organization, was considered to be a success, and came to an end in 2002. Continued monitoring ensures onchocerciasis cannot reinvade the area of the OCP.",
            "score": 96.5742416381836
        },
        {
            "docid": "6090525_72",
            "document": "Neglected tropical diseases . Mass drug administration is considered a possible method for eradication, especially for lymphatic filariasis, onchocerciasis, and trachoma, although drug resistance is a potential problem. According to Fenwick, Pfizer donated 70\u00a0million doses of drugs in 2011 to eliminate trachoma through the International Trachoma Initiative. Merck has helped The African Programme for the Control of Onchocerciasis (APOC) and Oncho Elimination Programme for the Americas to greatly diminished the effect of Onchocerciasis by donating ivermectin. Merck KGaA pledged to give 200\u00a0million tablets of praziquantel over 10 years, the only cure for schistosomiasis. GlaxoSmithKline has donated two\u00a0billion tablets of medicine for lymphatic filariasis and pledged 400\u00a0million deworming tablets per year for five years in 2010. Johnson & Johnson has pledged 200\u00a0million deworming tablets per year. Novartis has pledged leprosy treatment, EISAI pledged two\u00a0billion tablets to help treat lymphatic filariasis.",
            "score": 96.41233825683594
        },
        {
            "docid": "25015196_9",
            "document": "United Front Against Riverblindness . Onchocerciasis is a neglected tropical disease. The primary strategy to control onchocerciasis is to interrupt the life cycle of the parasite. Ivermectin, known by its trade name Mectizan, is the only drug available for treating onchocerciasis without severe side effects. The drug rapidly kills microfilariae (immature worms) but not the adult worms. A single oral dose of ivermectin, taken annually for the 10-15 year life span of the adult worms, protects individuals from further progression of onchocerciasis. Merck & Co. manufactures the drug and provides it free worldwide for the treatment of onchocerciasis.",
            "score": 95.65399932861328
        },
        {
            "docid": "276846_16",
            "document": "Onchocerciasis . In 1992, the Onchocerciasis Elimination Programme for the Americas, which also relies on ivermectin, was launched. On July 29, 2013, the Pan American Health Organization (PAHO) announced that after 16 years of efforts, Colombia had become the first country in the world to eliminate onchocerciasis. In September 2015, the Onchocerciasis Elimination Program for the Americas announced that onchocerciasis only remained in a remote region on the border of Brazil and Venezuela. The area is home to the Yanomami indigenous people. The first countries to receive verification of elimination were Colombia in 2013, Ecuador in 2014, and Mexico in 2015. Guatemala has submitted a request for verification. The key factor in elimination is mass administration of the antiparasitic drug ivermectin. The initial projection was that the disease would be eliminated from remaining foci in the Americas by 2012.",
            "score": 95.57505798339844
        },
        {
            "docid": "1539801_27",
            "document": "Brugia malayi . A goal of community-based efforts is to eliminate microfilariae from the blood of infected individuals in order to prevent transmission to the mosquito. This is primarily accomplished through the use of drugs. The treatment for \"B. malayi\" infection is the same as for Bancroftian filariasis. Diethylcarbamazine has been used in mass treatment programs as an effective microfilaricidal drug in several locations, including India. While diethylcarbamazine tends to cause adverse reactions like immediate fever and weakness, it is not known to cause any long-term adverse drug effects. It has been shown to kill both adult worms and microfilariae. In Malaysia, diethylcarbamazine dosages (6\u00a0mg/kg weekly for 6 weeks; 6\u00a0mg/kg daily for 9 days) reduced microfilariae by 80% for 18\u201324 months after treatment in the absence of mosquito control. Microfilariae numbers slowly return many months after treatment, thus requiring multiple drug doses over time in order to achieve long-term control. However, it is not known how many years of mass drug administration is required to eliminate transmission. there have been any confirmed cases of diethylcarbamazine resistance as of 2007.",
            "score": 94.28279876708984
        },
        {
            "docid": "336866_16",
            "document": "Filariasis . Filarial diseases in humans offer prospects for elimination by means of vermicidal treatment. If the human link in the chain of infection can be broken, then notionally the disease could be wiped out in a season. In practice it is not quite so simple, and there are complications in that multiple species overlap in certain regions and double infections are common. This creates difficulties for routine mass treatment because people with onchocerciasis in particular react badly to treatment for lymphatic filariasis.",
            "score": 92.41094207763672
        },
        {
            "docid": "1877407_14",
            "document": "Onchocerca volvulus . 99% of cases of onchocerciasis are found in 31 countries in Sub-Saharan Africa, although there are areas of limited transmission in Brazil, Venezuela and Yemen. The disease is thought to have been imported into Latin America through the slave trade. Onchocerciasis was eliminated from Colombia in 2013, Ecuador in 2014, Mexico in 2015 and Guatemala in 2016 due to control programs that used mass drug administration with ivermectin.",
            "score": 91.92589569091797
        },
        {
            "docid": "276846_2",
            "document": "Onchocerciasis . Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm \"Onchocerca volvulus\". Symptoms include severe itching, bumps under the skin, and blindness. It is the second-most common cause of blindness due to infection, after trachoma. The parasite worm is spread by the bites of a black fly of the \"Simulium\" type. Usually, many bites are required before infection occurs. These flies live near rivers, hence the common name of the disease. Once inside a person, the worms create larvae that make their way out to the skin, where they can infect the next black fly that bites the person. There are a number of ways to make the diagnosis, including: placing a biopsy of the skin in normal saline and watching for the larva to come out, looking in the eye for larvae, and looking within the bumps under the skin for adult worms. A vaccine against the disease does not exist. Prevention is by avoiding being bitten by flies. This may include the use of insect repellent and proper clothing. Other efforts include those to decrease the fly population by spraying insecticides. Efforts to eradicate the disease by treating entire groups of people twice a year are ongoing in a number of areas of the world. Treatment of those infected is with the medication ivermectin every six to twelve months. This treatment kills the larvae but not the adult worms. The antibiotic doxycycline weakens the worms by killing an associated bacterium called \"Wolbachia\", and is recommended by some as well. The lumps under the skin may also be removed by surgery. About 15.5 million people are infected with river blindness. Approximately 0.8 million have some amount of loss of vision from the infection. Most infections occur in sub-Saharan Africa, although cases have also been reported in Yemen and isolated areas of Central and South America. In 1915, the physician Rodolfo Robles first linked the worm to eye disease. It is listed by the World Health Organization (WHO) as a neglected tropical disease.",
            "score": 91.346435546875
        },
        {
            "docid": "27067_83",
            "document": "Sub-Saharan Africa . In 2011, Sub-Saharan Africa was home to 69% of all people living with HIV/AIDS worldwide. In response, a number of initiatives have been launched to educate the public on HIV/AIDS. Among these are combination prevention programmes, considered to be the most effective initiative, the abstinence, be faithful, use a condom campaign, and the Desmond Tutu HIV Foundation's outreach programs. According to a 2013 special report issued by the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of HIV positive people in Africa receiving anti-retroviral treatment in 2012 was over seven times the number receiving treatment in 2005, with an almost 1 million added in the last year alone. The number of AIDS-related deaths in Sub-Saharan Africa in 2011 was 33 percent less than the number in 2005. The number of new HIV infections in Sub-Saharan Africa in 2011 was 25 percent less than the number in 2001. Malaria is an endemic illness in Sub-Saharan Africa, where the majority of malaria cases and deaths worldwide occur. Routine immunization has been introduced in order to prevent measles. Onchocerciasis (\"river blindness\"), a common cause of blindness, is also endemic to parts of the region. More than 99% of people affected by the illness worldwide live in 31 countries therein. In response, the African Programme for Onchocerciasis Control (APOC) was launched in 1995 with the aim of controlling the disease. Maternal mortality is another challenge, with more than half of maternal deaths in the world occurring in Sub-Saharan Africa. However, there has generally been progress here as well, as a number of countries in the region have halved their levels of maternal mortality since 1990. Additionally, the African Union in July 2003 ratified the Maputo Protocol, which pledges to prohibit female genital mutilation (FGM).",
            "score": 89.79106140136719
        },
        {
            "docid": "1877407_10",
            "document": "Onchocerca volvulus . \"Onchocerca volvulus\" causes onchocerciasis, which causes severe itching. Long-term infection can cause keratitis, an inflammation of the cornea in the eye, and ultimately leads to blindness. Symptoms are caused by the microfilariae and the immune response to infection, rather than the adults themselves. The most effective treatment involves using ivermectin, although there are reports of resistance developing to this drug. Ivermectin prevents female worms from releasing microfilariae for several months, thus relieving symptoms and temporarily preventing transmission. However, this does not kill adult worms so it must be taken once annually as long as adult worms are present.",
            "score": 88.93772888183594
        },
        {
            "docid": "760951_19",
            "document": "Cysticercosis . The intervention strategies to eradicate cysticercosis includes surveillance of pigs in foci of transmission and massive chemotherapy treatment of humans. In reality, control of \"T. solium\" by a single intervention, for instance, by treating only human population will not work because the existing infected pigs can still carry on the cycle. The proposed strategy for eradication is to do multilateral intervention by treating both human and porcine populations. It is feasible because treatment pigs with oxfendazole have been shown to be effective and once treated, they are protected from further infections for at least 3 months.",
            "score": 88.61186218261719
        },
        {
            "docid": "203312_37",
            "document": "Management of HIV/AIDS . In the first 6 months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease. There may be special benefits to starting antiretroviral therapy early during this acute phase, including lowering the viral \"set-point\" or baseline viral load, reduce the mutation rate of the virus, and reduce the size of the viral reservoir (See section below on viral reservoirs). The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped. Since viral loads are usually very high during acute infection, this period carries an estimated 26 times higher risk of transmission. By treating acutely infected patients, it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are associated with lower risk of transmission (See section on treatment as prevention). However an overall benefit has not been proven and has to be balanced with the risks of HIV treatment. Therapy during acute infection carries a grade BII recommendation from the US DHHS.",
            "score": 88.1991195678711
        },
        {
            "docid": "6028064_11",
            "document": "Lymphatic filariasis . The World Health Organization recommends mass deworming\u2014treating entire groups of people who are at risk with a single annual dose of two medicines, namely albendazole in combination with either ivermectin or diethylcarbamazine citrate. With consistent treatment, since the disease needs a human host, the reduction of microfilariae means the disease will not be transmitted, the adult worms will die out, and the cycle will be broken. In sub-Saharan Africa, albendazole (donated by GlaxoSmithKline) is being used with ivermectin (donated by Merck & Co.) to treat the disease, whereas elsewhere in the world, albendazole is used with diethylcarbamazine. Transmission of the infection can be broken when a single dose of these combined oral medicines is consistently maintained annually for a duration of four to six years. Using a combination of treatments better reduces the number of microfilariae in blood. Avoiding mosquito bites, such as by using insecticide-treated mosquito bed nets, also reduces the transmission of lymphatic filariasis.",
            "score": 88.08319854736328
        },
        {
            "docid": "276846_19",
            "document": "Onchocerciasis . Ivermectin treatment is particularly effective because it only needs to be taken once or twice a year, needs no refrigeration, and has a wide margin of safety, with the result that it has been widely given by minimally trained community health workers.",
            "score": 87.91246795654297
        },
        {
            "docid": "889672_6",
            "document": "Tropical disease . Some examples of work include helping to develop new treatments for diseases, such as ivermectin for onchocerciasis (river blindness); showing how packaging can improve use of artemesinin-combination treatment (ACT) for malaria; demonstrating the effectiveness of bednets to prevent mosquito bites and malaria; and documenting how community-based and community-led programmes increases distribution of multiple treatments. TDR history",
            "score": 87.4937515258789
        },
        {
            "docid": "186647_2",
            "document": "Diethylcarbamazine . Diethylcarbamazine (DEC) is a medication used in the treatment of filariasis including lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It may also be used for prevention of loiasis in those at high risk. While it has been used for onchocerciasis (river blindness), invermectin is preferred. It is taken by mouth. Common side effects itching, facial swelling, headaches, and feeling tired. Other side effects include vision loss and dizziness. It is a recommended treatment in pregnancy and appears to be safe for the baby. The World Health Organization; however, recommends waiting until after pregnancy for treatment when feasible. It is made from piperazine. Diethylcarbamazine was discovered in 1947. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is less than 0.01 USD per dose. It is not commercially available in the United States but can be acquired from the Center for Disease Control.",
            "score": 87.31808471679688
        },
        {
            "docid": "41081621_6",
            "document": "Taenia hydatigena . Cysticercosis is rare in the U.S. and most parts of Europe. It is primarily found in immigrant species, or species that have arrived from another country. The main objectives are as follows: to reduce the chances of becoming infected, and, if infected, to reduce the chances of the infection being transmitted. Educating the general public will help change how the disease is perceived. This could help people better understand risks and allow people to not live in fear of the disease. The high prevalence of some zoonotic helminths could indicate that humans in specific regions such as; the mediterranean area, south of the Sahara in the semi-arid areas of East Africa, South Africa, South America, East Europe and parts of China. These areas are at serious risk of transmission and, if all the preventive measures are not taken, the human infection may spread quickly. Preventive programs, such as elimination of the stray dogs from cities and rural regions, could be necessary in this instance. However, control of wild canids can be difficult, but there are other regulatory measures that can be applied to communities, such as health education and implementing strict regulations of livestock slaughtering in slaughter houses and farms, could reduce the risk of parasite transmission. In addition, it is important for public health authorities, pet owners, physicians and veterinarians in these regions to pay close attention to patients and to remain informed of any possible outbreaks and transmission. In a study conducted at Washington State University, the effects of heat treatment were analyzed on the young forms of Taenia hydatigena. They observed that when the eggs were treated at temperatures of 60 degrees C they did not establish in the hosts. This could be influential in future prevention methods.",
            "score": 86.53304290771484
        },
        {
            "docid": "186641_46",
            "document": "Loa loa filariasis . An area of tremendous concern regarding loiasis is its co-endemicity with onchocerciasis in certain areas of west and central Africa, as mass ivermectin treatment of onchocerciasis can lead to serious adverse events (SAEs) in patients who have high \"Loa loa\" microfilarial densities, or loads. This fact necessitates the development of more specific diagnostics tests for \"Loa loa\" so that areas and individuals at a higher risk for neurologic consequences can be identified prior to microfilaricidal treatment. Additionally, the treatment of choice for loiasis, diethylcarbamazine, can lead to serious complications in and of itself when administered in standard doses to patients with high \"Loa loa\" microfilarial loads.",
            "score": 85.62637329101562
        },
        {
            "docid": "7800672_21",
            "document": "History of animal testing . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques and found long-term/high-dose treatments had adverse effects not found using short-term/high-dose treatment followed by long-term/low-dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques because an introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies are leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 85.19795227050781
        },
        {
            "docid": "8010519_40",
            "document": "Animal testing on non-human primates . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques, and found longterm-highdose treatments had adverse effects not found using short term-high dose treatment followed by long term-low dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques, because introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies is leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 85.19795227050781
        },
        {
            "docid": "16964126_44",
            "document": "Oesophagostomum . This follow-up to the original two-year study by J.B. Ziem saw collaboration with the Lymphatic Filariasis Elimination Programme, essentially expanding the scope of the Oesophagostomum Intervention Research Program that Ziem worked under. 11 villages across northeastern Ghana were given albendazole-ivermectin treatment and monitored for changes in prevalence; once again, decreases in both \"Oesophagostomum\" and hookworm infections occurred after two years of mass treatment. However, after interrupting mass treatment, Oesophagostomum prevalence continued to decrease even as hookworm prevalence increased again. Human oesophagostomiasis infection thus seems interruptible; even small numbers of persistent Oesophagostomum post-treatment were not sufficient to cause reinfection.",
            "score": 84.46163177490234
        }
    ]
}